natgillin/translations-raw huggingface dataset:
In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. 
Kod reakcija opisanih niže u ovoj specifikaciji može biti nužno zaštititi reaktivne funkcionalne skupine, primjerice hidroksi, amino, imino, tio ili karboksi skupine, gdje su te poželjne u konačnom produktu, kako bi se izbjeglo njihovo neželjeno sudjelovanje u reakcijama.
Dosages of the Compounds of the Present Disclosure 
Datum objave europske prijave patenta:
The compound of claim 1, wherein R1 is OR1'. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R1 je OR1′.
Locking system (1) according to Claim 7, characterized in that the locking element (17) is a locking rim. 
Sustav za zabravljivanje (1) u skladu s patentnim zahtjevom 6, naznačen time što je zabravljujući element (17) zabravljujući rub.
The flakes had a size from 2 mm to 10 mm. 
Pahuljice su veličine od 2 mm do 10 mm.
The process of Claim 1, wherein the Sr(OH)2 in step (a) is formed in situ by the addition of a SrO - comprising mineral, which is added prior to or during slaking and/or carbonation. 
Uporaba prema zahtjevu 1, gdje se Sr(OH)2 u koraku (a) formira in situ dodavanjem minerala koji sadrži SrO.
is a covalent bond or together with the —OC(═O)— group forms a self-immolative linker; and wherein the linker L is attached to a pyrrolobenzodiazepine (PBD) at the position of the asterisk (*), 
L? je kovalentna veza ili zajedno s -OC(=0)-skupinom, tvori samožrtvujuću poveznicu; i pri čemu je poveznica L priključena na pirolobenzodiazepin (PBD) na poziciji zvjezdice (*);
A method for preparing the pharmaceutical composition for use according to any one of claims 1∼8, characterized in that the method comprising following steps: preparation of #1 Extract: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis and Semen Cassiae are mixed, extracted by using heating refluxing with ethanol, and filtered to remove impurities; and the ethanol is recovered and concentrated to give #1 Extract for later use; preparation of #2 Extract: Radix Paeoniae alba is extracted by using heating refluxing with ethanol, and filtered; and the ethanol is recovered and concentrated to give #2 Extract for later use; 
Postupak za pripravu farmaceutskog pripravka za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time, da postupak obuhvaća slijedeće korake: a). Priprema ekstrakta br. 1: Radix Angelicae Sinensis, Rhizoma Chuanxiong, Rhizoma Corydalis i Semen Cassiae se pomiješaju, ekstrahiraju uz refluks i zagrijavanje s etanolom i filtriraju kako bi se uklonile nečistoće; i etanol se izdvaja i koncentrira kako bi se dobio ekstrakt br. 1 za kasniju uporabu; b). priprema ekstrakta br. 2: Radix Paeoniae alba se ekstrahira uz refluks i zagrijavanje s etanolom i filtrira; i etanol se izdvaja i koncentrira kako bi se dobio ekstrakt br. 2 za kasniju uporabu;
The forestry trailer with the mechanism for moving wheel axles according to any of the preceding claims, characterized in that the accessories (2c) of the chassis (2) are adapted to the shape of the parts (1a and 1b) of the chassis (1). 
Å umarska traktorska prikolica s mehanizmom za premještanje osovina kotača prema bilo kojem od prethodnih zahtjeva, naznačena time, da su dijelovi pribora (2c) šasije (1) prilagođeni obliku dijelova (1a 1 1b) šasije (1).
A suspension device according to claim 1, wherein the holder (3) is rigidly connected to the base part (4), the holder and the base part preferably being formed in one piece. 
Naprava za vješanje u skladu s bilo kojim od patentnih zahtjeva 1 - 6, naznačena time, da je držač (3) čvrsto spojen na temeljni dio (4), a držač i temeljni dio su poželjno oblikovani u jednom komadu.
BCH-encoding PLP data to generate an error protected data; 
BHC-kodiranje PLP podataka zbog stvaranja podataka zaštićenih od pogreške;
An inhaler according to claim 2, wherein the piercing member comprises at least two discrete piercing heads operable to pierce a corresponding number of holes in a blister aligned with the blister piercing member. 
Inhalator prema zahtjevu 2 ili 3, gdje dio za bušenje (9,75) obuhvaća barem dvije zasebne glave za bušenje kojo mogu probušiti odgovarajući broj rupica u blisteru koji je u ravnini s dijelom za bušenje blistera (9,75).
The ingredients used in the preparation of tablets containing nebivolol hydrochloride in the present invention by wet granulation method are given below along with the method of preparation of said tablets. 
Sastojci koji su rabljeni u pripremi tableta koje sadrže nebivolol hidroklorid u ovom izumu pomoću vlažne granulacije prikazani su dolje zajedno s postupkom pripreme spomenutih tableta.
The panel according to claim 1, wherein the first locking element is positioned at a distance from an upper side of the upward tongue and/or wherein the first locking element is positioned at a distance from an lower side of the upward tongue. 
Panel (1, 42, 43, 46, 53, 57) prema jednom od prethodnih patentnih zahtjeva, pri čemu je prvi element (23, 64) za zaključavanje izveden na udaljenosti od gornje stranice prema gore isturenog jezička (19, 61).
a preparation comprising, together with a pharmaceutically acceptable carrier or diluent, one anticancer agent selected from the group consisting of anticancer alkylating agents, anticancer antimetabolites, anticancer antibiotics, plant-derived anticancer agents, anticancer platinum-coordinatedcomplex compounds, anticancer camptothecin derivatives, anticancer tyrosine kinase inhibitors, monoclonal antibodies, interferons, biological response modifiers, and other anticancer agents or a pharmaceutically acceptable salt or ester thereof, wherein: 
pripravak koji sadrži, zajedno s farmaceutski prikladnim nosačem ili punilom, jedno sredstvo protiv raka odabrano iz grupe koju čine alkilirajući citostatici, antimetaboliti citostatici, citostatici antibiotici, biljni citostatici, platinom-koordinirani kompleksni spojevi citostatici, citostatici derivati kamptotecina, citostatici inhibitori tirozin kinaze, monoklonska protutijela, interferoni, modulatori biološkog odgovora, i drugi citostatici ili njihova farmaceutski prikladna sol ili ester, gdje:
The method according to claim 1, further comprising introducing a gas into the first chamber and sealing the first port after the pharmaceutical product in the first chamber has been lyophilized. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da nadalje uključuje uvođenje plina u prvu komoru (110) i brtvljenje prvog otvora (112) nakon što je farmaceutski proizvod u prvoj komori (110) liofiliziran.
<223> Chimeric Ab comprising sequences from mus musculus and homo sapiens 
<223> Konstrukt kimernog protutijela koji sadrži sljedove iz Mus musculus i
The method of E 16, wherein the first treatment period ends within 30 days after disappearance of all symptoms of the AOID. 
IL-17 antagonist za uporabu u skladu sa zahtjevom 16, naznačen time, da prvo razdoblje liječenja završava unutar 30 dana nakon nestanka svih simptoma AQID.
Use of a pharmaceutical composition according to any of claims 10 to 16 for the preparation of a vaccine against cancer. 
Korištenje farmaceutskog sastava sukladno bilo kojoj od tvrdnji 10 do 16 za pripremu cjepiva protiv raka.
represents a side chain of an amino acid selected from Asn, Asp, Gln, and Glu, substituted with alkyl or aralkyl; 
predstavlja bočni lanac u aminokiselini koju se bira između Asn, Asp, Gln, te Glu, supstituiran alkilom ili aralkil;
An antibody or antigen-binding fragment thereof specifically binding to a polypeptide consisting of (Gly-Ala)m dipeptide repeats, wherein m is an integer of 10 or more, at least three contiguous amino acids of the amino acid sequences according to SEQ ID NO: 3 at its C-terminus, and/or at least three contiguous amino acids of the amino acid sequences according to SEQ ID NO: 14 at its N-terminus, 
Antitijelo ili njegov antigen-vezujući fragment koji se specifično vežu za polipeptid koji se sastoji od (Gly-Ala)a ponavljajućeg dipeptida, pri čemu je a cijeli broj od 16 ili više, pri čemu antitijelo ili njegov antigen-vezujući fragment sadrži CDR3 sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu u skladu sa SEQ ID NO: 53; CDR2 sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu u skladu sa SEQ ID NO: 54; i CDR1 sekvencu lakog lanca koja sadrži aminokiselinsku sekvencu u skladu sa SEQ ID NO: 55. i
A process for the preparation of a compound of the formula I as claimed in any of claims 1 to 9, which comprises cyclizing a compound of the formula XV to a compound of the formula XVI, converting the compound of the formula XVI into a compound of the formula II, reacting the compound of the formula II with a compound of the formula III to give a compound of the formula IV, and converting the compound of the formula IV into a compound of the formula I, wherein the groups Ar, R3 and R4 in the compounds of the formulae II, III, IV, XV and XVI are defined as in the compounds of the formula I, the group G2 in the compounds of the formula XV is a hydroxy group or a nucleophilically substitutable leaving group, the group G3 in the compounds of the formulae XV and XVI is bromine or (C1-C4)-alkyl-O-, and the group Y in the compounds of the formulae III and IV is R50-O-C(O)-, H-C(O)- or NC-, wherein R50 is (C1-C4)-alkyl. 
R4 R3 IV naznačen time što se sastoji u cikliziranju spoja formule XV u spoj formule XVI, prevođenju spoja formule XVI u spoj formule II, reakciji spoja formule II sa spojem formule III kako bi se dobilo spoj formule IV, te prevođenju spoja formule IV u spoj formule I, gdje su skupine Ar, R3 i R4 u spojevima formula II, III, IV, XV 1 XVI definirane kao u spojevima formule I, skupina G2 u spojevima formule XV je skupina hidroksi ili izlazna skupina koju se može nukleofilno supstituirati, skupina G3 u spojevima formula XV i XVI je brom ili (C;-C,)-alkil-O-, a skupina Y u spojevima formula III i IV je R50-O-C(O)-, H-C(O)- ii NC-, gdje je R50 (C,-Ca)-alkil.
The PET container of claim 10 wherein the second endothermic glass transition temperature is at least 40° C. higher than the first endothermic glass transition temperature; preferably the second endothermic glass transition temperature is at least 50° C. higher than the first endothermic glass transition temperature. 
PET posuda iz patentnog zahtjeva 10 gdje je temperatura drugog endotermnog prelaza stakla najmanje 40* C. viša nego temperatura prvog endotermnog prelaza stakla; poželjno temperatura drugog endotermnog prelaza stakla je najmanje 50* €. viša nego temperatura prvog endotermnog prelaza stakla.
Cy1 is optionally further substituted by one to three independent occurrences of R6, wherein each occurrence of R6 is —OMe, methyl, ethyl, F, or Cl. 
Cy! je izborno supstituiran sa jednim do tri nezavisna R$, pri čemu je svaki R* jednak -OMe, metil, etil, F ili C1. .
The method of claim 2, wherein the pressure in said catalyst trough and said supercritical trough are identical, and the temperature in said catalyst trough and said supercritical trough are also identical. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što tlakovi u navedenom katalizatorskom koritu i navedenom superkritičnom koritu su isti, a i temperature u navedenom katalizatorskom koritu i navedenom superkritičnom koritu su također iste.
The use of any of claims 28 to 33, wherein the medicament is an aerosol having a mass median aerodynamic diameter from about 2 microns to about 5 microns with a geometric standard deviation less than or equal to about 2.5 microns, preferably from about 2.5 microns to about 4.5 microns with a geometric standard deviation less than or equal to about 1.8 microns, more preferred from about 2.8 microns to about 4.3 microns with a geometric standard deviation less than or equal to about 2 microns. 
Uporaba iz bilo kojeg od patentnih zahtjeva 28 do 33, pri čemu je lijek aerosol koji ima promjer srednje aerodinamične mase od oko 2 mikrona do oko 5 mikrona s geometrijskim standardnim odstupanjem manjim od ili jednakim sa oko 2,5 mikrona, preporučljivo od oko 2,5 mikrona do oko 4,5 mikrona s geometrijskim standardnim odstupanjem manjim od ili jednakim s oko 1,8 mikrona, još preporučljiivije od oko 2,8 mikrona do oko 4,3 mikrona s geometrijskim standardnim odstupanjem manjim od ili jednakim s oko 2 mikrona.
a cumulative total amount of proline per unit volume greater than approximately 2.5 mM; 
(vi) kumulativna ukupna količina prolina po jedinici volumena veća od približno 2,5 mM;
wherein the transfer channel (13) has a length of 3 to 20 mm. 
pri čemu prijenosni kanal (13) ima duljinu od 3 do 20 mm.
In other embodiments the security member can be inserted from the exterior of the packaging. 
U drugim ostvarenjima zaštitni član može biti umetnut iz vanjske strane pakiranja.
Table 1 Length:Number of Unsaturations 
Broj objave europskog patenta:
the amino acid sequence has a Glutamine (Gln, Q) at position 105, wherein said position is determined according to Kabat numbering; and ii) the amino acid sequence binds protein F of hRSV with the same or a higher affinity, wherein said affinity is measured by surface plasmon resonance, and/or the amino acid sequence has the same or a higher potency, wherein said potency is determined by microneutralization assay, compared to the amino acid sequence without the 3, 2 or 1 amino acid difference; 
sekvenca amino kiseline ima Glutamin (Gln, Q) na položaju 105, pri čemu se navedeni položaj određuje prema Kabatovom numeriranju; i ii) sekvenca amino kiseline veže protein F iz hRSV s istim ili višim afinitetom, pri čemu se navedeni afinitet mjeri površinskom plazmonskom rezonancijom, i/ili sekvenca amino kiseline ima istu ili višu potentnost, pri čemu se navedena potentnost određuje pomoću analize mikroneutralizacije, u usporedbi sa sekvencom amino kiseline bez 3, 2 ili 1 razlikom u aminokiselini;
11 b, a cigarette box as claimed has been made of cardboard and has the shape of a rectangular prism. 
11b, zahtijevana kutija za cigarete napravljena je od kartona 1 ima oblik pravokutne prizme.
For the determination of the capacity to inhibit the cytotoxicity induced by oxygen radicals Human Umbilical Vein Endothelial Cells (HUVEC) were used. 
Za određivanje sposobnosti inhibicije citotoksičnosti inducirane kisikovim radikalima upotrijebljene su humane endotelne stanice umbilikalne vene (Human Umbilical Vein Endothelial Cells, HUVEC).
The aseptic unit is ready for use upon removal of the seals. 
Aseptička jedinica je spremna za upotrebu neposredno nakon odstranjivanja brtvi.
The compound of claim 13 wherein R4 is -CO2R5 and R5 is hydrogen; or a pharmaceutically acceptable salt, a stereoisomer, a mixture of stereoisomers, or a tautomer thereof. 
R? je vodik; i R* je Ci2-alkil, pri čemu spomenuti C1.2-alkil je supstituiran sa-SO;H ili -CO>H; ili njegova farmaceutski prihvatljiva sol, stereoizomer, mješavina stereoizomera, ili njegov tautomer.
Pharmacokinetic parameters are determined using WinNonlin software (Pharsight Corp., Mountain View, Calif.). 
Farmakokinetički parametri određeni su softverom WinNonlin (Pharsight Corp., Mountain View, CA).
The method according to claim 2 or 3, characterised in that the urea resin has a vinyl resin or melamine resin additive so as to increase the flexibility of the panel (11). 
Metoda u skladu sa patentnim zahtjevima 2 ili 3, naznačena time da smola uree ima aditiv u vidu vinil smole ili melamin smole tako da povećava savitljivost panela (11).
wherein the plurality of contiguous unrearranged functional human λ light chain V (hVλ) gene segments and the plurality of contiguous unrearranged functional human λ light chain J (hJ λ) gene segments are operably linked to the mouse k light chain constant region gene such that the unrearranged light chain variable region is capable of rearranging to form a rearranged human λ light chain variable region and the mouse expresses antibodies comprising a light chain comprising a variable region encoded by the rearranged human λ light chain variable region and a constant region encoded by the mouse k light chain constant region gene. The mouse of claim 1, wherein the plurality of unrearranged hVλ gene segments are at least 12 hVλ gene segments. 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K. Genetski modificirani miš prema zahtjevu 4, naznačen time, što miš dodatno sadrži sekvencu humane Vx-JK međugenske regije koja se nalazi između humanih V2 genskih segmenata i humanih JA genskih segmenata.
The compound or a salt thereof according to claim 1, wherein said compound is selected from the group consisting of 
Spoj ili njegova sol prema zahtjevu 1, naznačen/a time, da je navedeni spoj odabran iz skupine koju čine:
Stabilised amorphous form of agomelatine of formula (I): characterised in that agomelatine is dispersed within a matrix as follows: 
Stabilizirani amorfni oblik agomelatina formule (I): [image] naznačen time, da se agomelatin disperzira unutar matrice kako slijedi:
An anti IL-1B antibody or binding fragment thereof for use of claim 18, wherein said at least one pharmaceutical composition comprising an active agent other than an anti IL-1B antibody or binding fragment thereof is selected from the group consisting of a nonsteroidal anti-inflammatory drug (NSAID), a corticosteroid, an adrenocorticotropic hormone, and a colchicines. 
Anti-IL-1B protutijelo ili njegov IL-1B-vezujući fragment za uporabu prema zahtjevu 13, gdje se taj barem jedan farmaceutski oblik koji sadrži djelatnu tvar koja nije IL-1B protutijelo ili fragment izabire iz skupine koja obuhvaća nesteroidni protuupalni lijek (NSAID), kortikosteroid, adrenokortikotropni hormon i kolhicin.
The oil according to claim 1 comprising a lipid fraction comprising: 15.6% saturated fatty acids by weight, 32.1% monounsaturates by weight, 52.2% polyunsaturates (C18:2 and C18:3) by weight of which 1.1% by weight is Omega 3 fatty acids and also comprising: 0.021% vitamin E over the total weight of the lipid fraction and 0.04% y-oryzanol over the total weight of the lipid fraction. 
Ulje prema zahtjevu 22, naznačeno time, da obuhvaća lipidnu frakciju koja sadrži: 15,6 masenih % zasićenih masnih kiselina, 32,1 masenih % jednostruko nezasićenih masnih kiselina, 52,2 masenih % višestruko nezasićenih masnih kiselina (vitamin F), od kojih je 1,1 maseni % omega 3, te također sadrži 0,021 % vitamina E preko ukupne mase lipidne frakcije i 0,04 % y-orizanola preko ukupne mase lipidne frakcije.
A cryogenic tank arrangement according to claim 6, wherein the branch conduits are arranged inside the tank and arranged parallel with, and in the vicinity of a wall of the tank body. 
Kriogeni spremnik prema zahtjevu 4, naznačen time da su vodovi grananja (32',32") smješteni unutar spremnika i postavljeni su paralelno sa, te u blizini stjenke tijela spremnika (12).
These compounds may especially be used in the prevention and/or treatment of pathological conditions, where oxidative stress plays an important role in their pathogenesis, such as allergy, stroke, Alzheimer's disease, and/or ischemic cardiovascular diseases. 
Ti spojevi se mogu posebno upotrijebiti u prevenciji i/ili hječenju patoloških stanja u čijoj patogenezi ima važnu ulogu oksidativan stres, kao što je alergija, udar kapi, Alzheimerova bolest, i/ili ishemijske kardiovaskularne bolesti.
retain in an inner chamber a first insulation layer of the fiber optic cable that encases the optical fibers; 
zadržavanje u unutarnjoj komori (62) prvog sloja izolacije (66) optičkog kabela (20) koji zatvara optička vlakna (60);
A packaging according to any of the preceding claims, wherein the first and/or second outer part comprises a decoration. 
Pakiranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačeno time, što prvi i/ili drugi vanjski dio sadržava dekoraciju.
A synergistic herbicidal mixture as claimed in claim 1 in which the sulfonyl urea is selected from the group consisting of nicosulfuron, tritosulfuron, mesosulfuron, cyclosulfamuron, rimsulfuron, foramsulfuron including their respective isomers as well as their respective environmentally compatible salts or esters or amides or other derivatives. 
Sinergistička herbicidna smjesa koja sadrži A) imazamoks kao i njegove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom; i B) metazaklor i kvinmerak uključujući njihove odgovarajuće izomere, kao i njihove odgovarajuće soli, estere, amide ili druge derivate kompatibilne sa životnom sredinom.
These compositions apply in particular to compositions that have been reconstituted after lyophilisation, and the value of t can be lower before lyophilisation and reconstitution (Figure 14). 
Ovi sastavi osobito se primjenjuju za sastave koji su se već rekonstituirali nakon liofilizacije, i vrijednost Tr može biti niža prije liofilizacije i rekonstitucije (Slika 14).
The granulate showed the following particle size distribution: 
Dobiveni granulat pokazivao je slijedeću raspodjelu veličine čestica:
The replaceable printer component (108) of claim 1, wherein each tag (T0-T15) defines a type and a length of the data stored in a portion. 
Zamjenjiva komponenta pisača (108) u skladu s patentnim zahtjevom 1, naznačena time što svaka oznaka (TO- T15) definira tip i duljinu podataka spremljenih u dijelu.
recovery of the solid precipitated in step d), to give the crystalline form A of SAG. 
izolacija krutine istaložene u koraku d), čime se dobiva SAG kristaliničnog oblika A.
The residue was dissolved using ethyl acetate (200 ml), the solution washed with water (2 x 50 ml), the organic phase dried over anhydrous magnesium sulphate and after filtration, concentrated under reduced pressure to give a yellow foam. 
Ostatak se otopi korištenjem etil acetata (200 ml), otopina se ispere vodom (2 x 50 ml), organska faza se suši iznad anhidridnog magnezij sulfata i nakon filtriranja se koncentrira uz smanjeni tlak dajući žutu pjenu.
the main species HER2 antibody with a sialidated oligosaccharide structure attached to an Fc region thereof. 
glavni rod HER2-protutijela sa sialidiranom strukturom oligosaharida, priključenom na njegovo Fc-područje.
Composition according to claim 2 wherein the red blood cells in the form of an immune complex are heat-treated or chemically treated. 
Pripravak za uporabu prema zahtjevu 2 naznačen time da su crvene krvne stanice u obliku imunološkog kompleksa toplinski obrađene ili kemijski obrađene.
The composition according to the present invention is preferably formulated in the forms of a solution and/or suspension and/or powder to be reconstituted in water, more preferably in the form of an aqueous suspension. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time što je u obliku otopine i/ili suspenzije i/ili praha koji se treba rekonstituirati u vodi, po mogućnosti u obliku vodene suspenzije.
A combination suitable for the treatment of cancer comprising a compound of the Formula I, or a pharmaceutically-acceptable salt thereof, according to any one of claims 10 and 12 which is 8-((1R)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide and a taxoid. 
Kombinacija pogodna za liječenje raka koja sadrži spoj s formulom I, ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 10 i 12 naznačena time da je 8-Â«((1R)-1-(3,5-difluorofenilamino)etil)-N,N-dimetil-2-morfolino-4-okso-4H-kromen-6-karboksamid i taksoid.
a Long Term Evolution technology, 
- Tehnologija napredne dugoročne evolucije,
Wind system (1) according to claim 1, characterised in that said kites (2) are equipped with an actuating and stabilising system of a sideslip manoeuvre. 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da se spomenuti spojler pokreće preko sustava sa samostalnim napajanjem.